Author

L. Wyrwicz

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

BACKGROUND Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....

K. Kato, J. Ajani, Y. Doki et al. · Annals of Oncology · 2 citations

Review Open access Sep 2026

Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

Background KEYNOTE-859 showed a favorable benefit–risk profile for pembrolizumab plus chemotherapy compared with placebo plus chemotherapy, regardless of programmed death-ligand 1 (PD-L1) status, in participants with untreated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastr...

S. Rha, L. Wyrwicz, P. Yanez et al. · ESMO Open · 0 citations